In a new statement, the World Health Organization revealed that it allows the use of the drug tocilizumab to treat severe cases of corona, explaining that tocilizumab is a monoclonal antibody, which inhibits the interleukin-6 (IL-6) receptor, and interleukin-6 stimulates the response. It is found in high levels in patients with severe symptoms of corona.
Clinical studies have shown that intravenous tocilizumab reduces mortality in some severely ill MERS-CoV patients, rapidly deteriorating health, increased oxygen needs and a significant inflammatory response.
The World Health Organization stresses the need for the drug to be administered by health workers in a controlled clinical setting, in addition to the usual care for coronavirus, which includes oxygen, corticosteroids and other medications.
And Dr. Tedros Adhanom Gebresius, Director-General of the World Health Organization, had confirmed in a new statement to him that two years ago, while the world was still dealing with the spread of the virus. Corona What’s new, the WHO has done a lot, adding: “We have gathered with hundreds of scientists from around the world to identify the most urgent priorities in research and development.”
Today marks the second anniversary of that first meeting of the World Health Organization, explaining that it is astonishing to think that within a year of this meeting, the first vaccines were approved, and only two years later, more than 10 billion doses were administered globally.
Tedros said: The development and approval of several vaccines in record time is an extraordinary scientific victory that sets a new standard, pointing out that there can be no doubt that vaccines have saved countless lives, help turn the tide of the epidemic, and now give many countries the confidence to mitigate restrictions.
“But as you know, this scientific victory has been marred by wide inequalities of access,” he added. “More than half of the world’s population is now fully immunized. However, 84% of Africa’s population has not yet received a single dose, and a large part of this disparity is due to Due to the fact that global vaccine production is mostly concentrated in a few high-income countries, one of the most obvious lessons of the epidemic is the urgent need to increase domestic production of vaccines, especially in low- and middle-income countries.
